Insulin human
- Generic Name
- Insulin human
- Brand Names
- Actraphane, Actrapid, Afrezza, Entuzity, Exubera, Humulin, Humulin N, Humulin R, Insulatard, Insuman, Myxredlin, Novolin, Novolin N, Novolin R, Protaphane, Mixtard
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 11061-68-0
- Unique Ingredient Identifier
- 1Y17CTI5SR
- Background
Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mellitus, insulin is a peptide hormone prod...
- Indication
Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Type 1 Diabetes Mellitus
- Associated Therapies
- -
Human Models of Selective Insulin Resistance: Pancreatic Clamp
- Conditions
- Interventions
- Drug: Insulin humanDrug: Octreotide AcetateDrug: GlucagonDrug: Growth Hormone, HumanDrug: 20% D-glucose (aq)Diagnostic Test: [6,6-2H2] D-glucoseDiagnostic Test: [1-13C1] sodium acetateDietary Supplement: Nestle BOOST PlusDietary Supplement: KIND BarDevice: Harvard Apparatus PHD ULTRA CP syringe pumpDevice: Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 36
- Registration Number
- NCT06558422
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia
- Conditions
- Interventions
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 90
- Registration Number
- NCT06178874
- Locations
- 🇪🇬
Ain shams university, Cairo, Egypt
Dexamethasone/Pancreatic Clamp P&F
- Conditions
- Interventions
- Drug: Insulin humanDrug: Octreotide AcetateDrug: GlucagonDrug: Human Growth HormoneDrug: Dexamethasone OralOther: [6,6-2H2] D-glucoseDrug: 20% D-glucose (aq)Dietary Supplement: BOOST PlusDevice: Harvard Apparatus PHD ULTRA CP syringe pumpDevice: Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate AnalyzerOther: Normal salineOther: Human albumin
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Columbia University
- Registration Number
- NCT06126354
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
5 Versus 10 Units of Insulin in Hyperkalemia Management
- Conditions
- Interventions
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Oman Medical Speciality Board
- Target Recruit Count
- 336
- Registration Number
- NCT06036823
- Locations
- 🇴🇲
Sultan Qaboos University hospital, Seeb, Muscat, Oman
Pancreatic Clamp in NAFLD
- Conditions
- Interventions
- Drug: Insulin humanDrug: Octreotide AcetateDrug: GlucagonDrug: Growth Hormone, HumanOther: [6,6-2H2] D-glucoseDrug: 20% D-glucose (aq)Dietary Supplement: BOOST PlusDietary Supplement: CORE BarDevice: Harvard Apparatus PHD ULTRA CP syringe pumpDevice: Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 42
- Registration Number
- NCT05724134
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
Dose Response Study of Transdermal Human Insulin in Patients
- Conditions
- Interventions
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Transdermal Delivery Solutions Corp
- Target Recruit Count
- 30
- Registration Number
- NCT05159453
- Locations
- 🇺🇸
Langford Research Institute, Palm Beach Gardens, Florida, United States
Impact of Intranasal Insulin on Sympathetic Activity and Cerebral Vasodilation
- Conditions
- Interventions
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- University of Missouri-Columbia
- Target Recruit Count
- 65
- Registration Number
- NCT05153395
- Locations
- 🇺🇸
University of Missouri, Columbia, Missouri, United States
Metabolic Adaptation to High-frequent Hypoglycaemia in Type 1 Diabetes
- Conditions
- Interventions
- Drug: insulin humanDrug: EpinephrinProcedure: Muscle biopsyProcedure: Adipose tissue biopsyDrug: GlucagonDevice: IPRO 2 Medtronic MinimedProcedure: 7 Tesla (7T) Magnetic Resonance ImagingProcedure: Indirect Calorimetry using Jaeger Oxycon ChampionProcedure: Core temperature and thermography using Thermovision SC645Device: Freestyle Libre 2
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Nordsjaellands Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05095259
- Locations
- 🇩🇰
Nordsjaellands Hospital, Hillerød, Denmark
🇩🇰Steno Diabetes Center Copenhagen, Gentofte, Denmark
A Study Evaluating the Bioavailability of Oral Insulin (N11005)
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Beijing Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT04975022
- Locations
- 🇨🇳
Beijing Hospital, Beijing, China
Afrezza® INHALE-1 Study in Pediatrics
- Conditions
- Interventions
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Mannkind Corporation
- Target Recruit Count
- 319
- Registration Number
- NCT04974528
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Rocky Mountain Clinical Research, Idaho Falls, Idaho, United States
🇺🇸Joe DiMaggio Children's Hospital, Hollywood, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.